New drug cocktail aims to stop itchy eyes from birch pollen

NCT ID NCT06602739

Completed Symptom relief Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two experimental drugs, REGN5713 and REGN5715, given together to reduce eye allergy symptoms caused by birch pollen. Fifty-four adults with a history of moderate to severe birch pollen allergy received the drug combo or a placebo. The main goal was to see if the drugs could lower itch and redness during a controlled allergen challenge.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN5713 (bremzalerbart) and REGN5715 (atisnolerbart) given together
What this could lead to: If it works, this could provide a new treatment option for people with birch pollen allergy who suffer from itchy, red eyes.
What could go wrong: This trial is small (54 participants) and completed, so results may not apply to everyone. The drugs are experimental and may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC CONJUNCTIVITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic conjunctivitis Conjunctivitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIC CONJUNCTIVITIS

Contacts and locations

Locations

Andover Eye Associates

Andover, Massachusetts, 01810, United States
Clinique de Specialisee en Allergie de la Capitale

Québec, G1V 4W2, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.